# **Epidemiology of Atrial Fibrillation in Colombia 2010-2015**

Pablo Andrés Miranda-Machado MD, MSc<sup>1</sup> Roberto Carlos Guzman-Saenz MD<sup>2</sup>

- 1. Epidemiologia, ALZAK Foundation. Cartagena, Colombia\*
- 2. Universidad Norte. Barranquilla, Colombia.

\*Email: mmpa9@hotmail.com

\*ORCID: https://orcid.org/0000-0002-6790-7112?lang=es

<sup>\*</sup>Corresponding autor

## **Epidemiology of Atrial Fibrillation in Colombia 2010-2015**

Pablo Miranda-Machado, MD, MSc<sup>1</sup>; Roberto Guzman-Saenz, MD<sup>2</sup>.

- 1. ALZAK Foundation, Cartagena, Colombia.
- 2. Universidad Norte, Barranquilla, Colombia

#### **Abstract**

Atrial Fibrillation (AF) is a common cardiac arrhythmia. Its prevalence worldwide has doubled in the last decade due to increased capacity for diagnosis and management of heart disease and chronic non-cardiac. The purpose of this study was to estimate the prevalence, incidence and demand for treatment of AF in Colombia during the period 2010 to 2015.

Key words: atrial fibrillation, epidemiology, prevalence, incidence, demand for care, Colombia.

### Introduction

Atrial Fibrillation (AF) is the most frequent and most important cardiac arrhythmia of the clinical practice in the adult population. Both due to its incidence, which increases with age, and due to its morbidity and mortality given its ability to cause cardioembolic and cerebrovascular events (1). The main risk factor for developing AF is the age of the patient. The older the age the higher the incidence. Arterial hypertension, diabetes, heart failure are also found as the main risk factors. Other related risk factors are hyperthyroidism, maternal obesity and high birth weight (greater than 3.5 kg), fatty liver, consumption of alcohol and hallucinogenic drugs. The important thing is that these risk factors are potentially modifiable, by changing lifestyles and therapeutic interventions (2-8). It requires the efforts of the primary care physician for prompt recognition through basic tests as the electrocardiogram (EKG)(9) in older adults with risk factors (high blood pressure (hypertension), diabetes mellitus (DM), cerebrovascular disease, heart failure, valvular disease, coronary heart disease, etc). and rigorous screening in second and third level centers in patients with acute cerebrovascular events with medium complexity tests such as 24-hour ambulatory EKG monitoring, continuous in-hospital EKG monitoring and echocardiography (10,11). This will allow a timely start treatment to control heart rate and / or control the pace, and above all prevent stroke with oral anticoagulation (12,13).

The global prevalence of AF is 1-2%. Its increases with age and it is estimated that the risk of developing this arrhythmia after 40 years of age is 25%. It occurs more in men than in women and is identified in 1 in 20 patients who present cerebrovascular events (14). The global prevalence of 33.5 million patients was estimated for 2010, in the United States, with a prevalence of 5.0% of the population. Approximately 5.2 million patients, with an annual incidence of 1.2 million patients. For Latin America the prevalence figure was estimated at 1.5 to 2.0% of the population, approximately 7 million patients, in Brazil alone it is estimated at 1.5 million patients.

The prevalence of cerebrovascular disease (CVA) in Latin America ranges between 5.7 and 7.7 / 1000 inhabitants, of which about 10% of all hospitalized patients in Mexico and Brazil documented atrial fibrillation, and 8% in Argentina. In China, in 2008, a prevalence of 0.9% of the population over 30 years of age was estimated, from which a risk of cerebrovascular events of 12.5% was calculated with respect to 2.5% of the general population without fibrillation atrial (AF) (1,2,15–17). The purpose of this study was to estimate the prevalence, incidence and demand for AF care in Colombia between 2010 and 2015.

#### Methods

A cross-sectional study was carried out. The total number of people that attended nationwide who had a diagnosis of AF (ICD-10 I48X) was included in the Database of the Social Protection Information System (SISPRO) for the period between 2010 and 2015. To estimate the prevalence, all types of diagnosis were included and new confirmed diagnoses were included to estimate the incidence. For the adjustments of the prevalence and incidence, the estimates of the national population of the National Department of Statistics (DANE) for the period between 2010 and 2015 were included. To estimate the prevalence of demand for care, the total number of people served at the nationwide registration in the SISPRO Database, between the period 2010 and 2015 was included. The qualitative and quantitative variables were expressed in percentages, and means with standard deviations respectively. All estimates were adjusted for age and sex.

#### Results

Between 2010 and 2015, a total of 112,353 people attended with a diagnosis of AF, were identified for an average of 22,470 + 6,413 patients with a diagnosis of AF per year. The prevalence of AF estimated in 2010 and 2015 was 22.6 and 51.4 per 100,000, respectively; and more than 60% of the patients were older than 65 years. The prevalence of AF in women and men in 2010 was 22.6 and 22.5 per 100,000, respectively. In 2015, the prevalence of AF in women and men was 51.2 and 51.5 per 100,000. In patients between 40-45 years, the prevalence of AF was higher in men in both 2010 and 2015 (2010 men 10.1 per 100,000 vs. women 5.8

per 100,000, 2015 men 16.2 per 100,000 vs. women 9.9 per 100,000) (Table 1-5). A total of 173,784 people treated with a newly confirmed diagnosis of AF were identified between 2010 and 2015, for an average of 2,897 + 887 patients with a new diagnosis of AF each year. The estimated incidence of AF in 2010 and 2015 was 4.1 and 8.0 per 100,000 respectively; and more than 66% of the patients were older than 65 years. The incidence of AF in women and men in 2010 was 4.2 and 3.9 per 100 thousand, respectively. In 2015, the incidence of AF in women and men in 2015 was 8.1 and 7.8 per 100,000. In patients between 40-45 years, the incidence of AF was similar between men and women in both 2010 and 2015 (2010 men 1.2 per 100,000 vs. women 1.3 per 100,000, 2015 men 1.9 per 100,000 vs. women 1.0 per 100 thousand) (Table 1,2, 6-8).

Between 2010 and 2014, 134,774,182 care services were provided by the general health social security system, for an average of 22,462,363 + 2,670,964 care services per year. The demand of care for AF in 2010 and 2015 was 0.05% and 0.10%, respectively. The demand of care for AF in women and men in 2010 was 4.2 and 3.9 per 100,000, respectively. In 2015, the demand of care for women and men was 8.1 and 7.8 per 100,000 (Table 2).

#### **Discussion**

In our study, an AF prevalence of 0.05% was estimated, 0.38% in those older than 18 years of age, and an increase of 150% was evident between 2010 and 2015. This prevalence is lower than the global regional report, and other AF prevalence studies nationwide. The global prevalence of AF ranges from 0.4% to 2.0%, and may reach 2.5% in those older 60 years old. An increase in its prevalence is expected in the next 50 years (14,18). This study found a prevalence of 0.02% FA in patients between 40 and 50 years of age, 1.9% in patients older than 80 years of age was estimated. No differences were found by sex, except in the age group between 40-50 years old where men predominated. Globally, a prevalence of <0.5% at 40–50 years and 5–15% at 80 years has been reported, and it affects men more (14). An average of more than 2,500 new cases of AF were estimated each year, in both men and women. Globally, an incidence of 2000 per 100,000 has been reported in both sexes (18).

Regarding epidemiological studies of AF in Colombia, previous studies are scarce and have estimated higher prevalences than those reported in our study. In the study of prevalence of AF in those older than 60 years old in a population of a Colombian university hospital based on more than 2000 EKG records, a crude and adjusted prevalence of AF in those older than 60 years old was estimated at 4.8% and 3.6%, respectively. The authors of this study recognized that because the estimates came from a single source, specifically from a high complexity hospital, it does not allow the results to be generalized to the entire Colombian population (19). In the study of the prevalence of AF in a population with cardiovascular risk factors of more than 4,700 people affiliated to a healthcare provider, an AF

prevalence of 0.15% was estimated. In those older than 60 years of age a prevalence of 1.6% was estimated. This estimate is similar to that reported in the present study (20). In the cross-sectional study based on a population older than 18 years old from a specific health department, within the framework of the AFINVA registry (Actuality in Non-Valvular Atrial Fibrillation), an AF prevalence of 2.1% and 8.06% in those over 65 years of age was estimated. The authors of this study recognized that the cross-sectional design used, could influence a possible overestimation of prevalence (21).

Regarding the limitations of this study, we did not have access to the medical records and EKG records of the patients who had registered diagnosis of AF in the SISPRO database, which was a major disadvantage. This database registers only the population that has demanded services for a specific period of time, which can be a limitation when extrapolating to the entire population of the country. The adjustment based on population projections from the DANE 2005 census may influence these estimates. However, we considered that the information sources used, have improved in their completeness and quality of the data, which makes evident the information on AF in Colombia with relative strength (22).

#### Conclusions

The prevalence of AF in Colombia in the population that used healthcare services is approximately 0.05% (51.4 per 100,000). Given the previous data based on cross-sectional population studies, and the limitations to generalize the results. A 66% underreporting in the diagnosis of AF can be estimated in the SISPRO database.

## **Highlights**

- AF is the most frequent and most important cardiac arrhythmia in the clinical practice of the adult population, both due to its incidence, and increasing age.
- AF is important for its morbidity and mortality due the ability to cause cardioembolic and cerebrovascular events.
- The global prevalence of AF is 1-2%, it increases with age and it is estimated that the risk of developing this arrhythmia throughout life after the age of 40 is 25%.
- Population studies have estimated a prevalence of AF in Colombia of 0.15%. and from 1.6% to 4.8% in those over 60 years of age.
- The prevalence of AF in Colombia of the population that used healthcare services is approximately 0.05% (51.4 per 100,000).

• An underreporting of 66% in the diagnosis of AF can be estimated in the SISPRO database.

#### References

- Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide Epidemiology of Atrial Fibrillation. Circulation [Internet]. 2014 Feb 25 [cited 2019 Jan 28];129(8):837–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24345399
- Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population. Am J Cardiol [Internet]. 2013 Oct 15 [cited 2019 Jan 28];112(8):1142–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23831166
- 3. Kallistratos M., Poulimenos LE, Manolis AJ. Atrial fibrillation and arterial hypertension. Pharmacol Res [Internet]. 2018 Feb [cited 2019 Jan 28];128:322–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29055746
- Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol [Internet]. 2017 Dec 29 [cited 2019 Jan 28];16(1):120. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28962617
- 5. Baumgartner C, da Costa BR, Collet T-H, Feller M, Floriani C, Bauer DC, et al. Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation. Circulation [Internet]. 2017 Nov 28 [cited 2019 Jan 28];136(22):2100–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29061566
- Johnson LSB, Salonen M, Kajantie E, Conen D, Healey JS, Osmond C, et al. Early Life Risk Factors for Incident Atrial Fibrillation in the Helsinki Birth Cohort Study. J Am Heart Assoc [Internet]. 2017 Nov 6 [cited 2019 Jan 28];6(6). Available from: http://www.ncbi.nlm.nih.gov/pubmed/28649086
- 7. Mantovani A. Nonalcoholic Fatty Liver Disease (NAFLD) and Risk of Cardiac Arrhythmias: A New Aspect of the Liver-heart Axis. J Clin Transl Hepatol

- [Internet]. 2017 Jun 28 [cited 2019 Jan 28];5(2):134–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28660151
- 8. Dixit S, Alonso A, Vittinghoff E, Soliman E, Chen LY, Marcus GM. Past alcohol consumption and incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study. Strnad P, editor. PLoS One [Internet]. 2017 Oct 18 [cited 2019 Jan 28];12(10):e0185228. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29045461
- Mant J, Fitzmaurice DA, Hobbs FDR, Jowett S, Murray ET, Holder R, et al. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ [Internet]. 2007 Aug 25 [cited 2019 Jan 28];335(7616):380. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17604299
- Wachter R, Gröschel K, Gelbrich G, Hamann GF, Kermer P, Liman J, et al. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF RANDOMISED): an open-label randomised controlled trial. Lancet Neurol [Internet]. 2017 Apr [cited 2019 Jan 28];16(4):282–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28187920
- 11. Gumbinger C, Krumsdorf U, Veltkamp R, Hacke W, Ringleb P. Continuous monitoring versus HOLTER ECG for detection of atrial fibrillation in patients with stroke. Eur J Neurol [Internet]. 2012 Feb [cited 2019 Jan 28];19(2):253–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21895885
- 12. Sethi NJ, Safi S, Nielsen EE, Feinberg J, Gluud C, Jakobsen JC. The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. Syst Rev [Internet]. 2017 Dec 6 [cited 2019 Jan 28];6(1):47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28264715
- 13. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. N Engl J Med [Internet]. 2002 Dec 5 [cited 2019 Jan 28];347(23):1825–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12466506
- 14. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J [Internet]. 2010 Oct 1 [cited 2019 Jan 28];31(19):2369–429. Available from: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehq278
- 15. Cantú-Brito C, Sampaio Silva G, Ameriso SF. Embolic Stroke of Undetermined Source in Latin America. Neurologist [Internet]. 2017 Sep [cited 2019 Jan 28];22(5):171–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28859022
- 16. Zhou Z, Hu D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol [Internet]. 2008 [cited 2019 Jan 28];18(5):209–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18776706
- 17. Bartholomay E, Polli I, Borges AP, Kalil C, Arroque A, Kohler I, et al.

- Prevalence of oral anticoagulation in atrial fibrillation. Clinics (Sao Paulo) [Internet]. 2014 Sep [cited 2019 Jan 28];69(9):615–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25318093
- Pava-Molano LF, Perafán-Bautista PE. Generalidades de la fibrilación auricular. Rev Colomb Cardiol [Internet]. 2016 Dec 1 [cited 2019 Jan 28];23:5–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0120563316301589
- 19. Rosselli D, Rodríguez AJ, García ÁA, Rueda JD. Prevalencia de fibrilación auricular en un hospital universitario colombiano. Rev Colomb Cardiol [Internet]. 2013 Nov 1 [cited 2019 Jan 28];20(6):383–5. Available from: https://www.sciencedirect.com/science/article/pii/S0120563313700895
- Marrugo R. El costoso riesgo de padecer Fibrilación Auricular en Colombia -Bayer Andina [Internet]. [cited 2019 Jan 28]. Available from: https://andina.bayer.com/es/sala-de-prensa/el-costoso-riesgo-de-padecer-fibrilacion-auricular-en-colombia.php
- 21. Mora-Llabata V, Dubois-Marqués D, Roldán-Torres I, Mateu-Navarro C, Sanz-García JJ, Moreno-Ballester V, et al. Prevalencia de fibrilación auricular y características de la fibrilación auricular no valvular en la población general. Registro AFINVA. Rev Colomb Cardiol [Internet]. 2017 Jan 1 [cited 2019 Jan 28];24(1):26–33. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0120563316300079
- 22. Ministerio de Salud y Protección Social. Analisis De Situación De Salud (ASIS) Colombia, 2017 [Internet]. [cited 2018 Nov 6]. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/PS P/asis-nacional-2017.pdf
- 23. Lévy S, Camm AJ, Saksena S, Aliot E, Breithardt G, Crijns HJGM, et al. International consensus on nomenclature and classification of atrial fibrillation: A collaborative project of the Working Group on Arrhythmias and the Working Group of Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. J Cardiovasc Electrophysiol [Internet]. 2003 Apr [cited 2019 Jan 28];14(4):443–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12741724
- 24. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med [Internet]. 2007 Jun 19 [cited 2019 Jan 28];146(12):857–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17577005
- 25. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med [Internet]. 2009 Sep 17 [cited 2019 Jan 28];361(12):1139–51. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0905561
- 26. ROCKET AF Study Investigators. Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study. Am Heart J [Internet]. 2010 Mar [cited 2019 Jan 28];159(3):340–347.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20211293

27. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med [Internet]. 2011 Sep 15 [cited 2019 Jan 28];365(11):981–92. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1107039

Funding: Authors' own resources.

## **Ethical Responsibilities:**

**Protection of people and animals:** The authors declare that no experiments were carried out on humans or animals for this research.

**Data confidentiality:** The authors declare that no patient data appears in this article.

**Right to privacy and informed consent:** The authors declare that no patient data appears in this article.

**Conflicts of interest:** The authors declare that they have no conflict of interest.

Table 1. Epidemiology of AF in Colombia 2010-2015. Source: SISPRO-DANE.

Epidemiology AF Colombia	2010	2011	2012	2013	2014	2015	TOTAL
Prevalence (cases x 100 thousand)	22.6	30.5	36.3	40.4	55.1	51.4	30.81
Incidence (cases x 100 thousand)	4.1	4.9	5.2	6.3	8.1	8.0	6.10
Demand of care (%)	0.05	0.06	0.07	0.08	0.10	0.10	77.52

Table 2. Total population, attended population and cases of AF in Colombia 2010-2015. Source: SISPRO-DANE.

Total population, attended and cases	2010	2011	2012	2013	2014	2015
Total population	45509584	46044601	46581823	47121089	47661787	48203405
Attended population	18637420	20797416	22421024	22273815	26289936	24354571
Prevalent cases AF	10303	14038	16901	19073	27231	24807
Incident cases AF	1870	2254	2423	2973	3989	3876

Table 3. Prevalent cases of AF in Colombia 2010-2015 for ages. Source: SISPRO.

Ages	2010	2011	2012	2013	2014	2015
De 0 a 4 years	15	20	31	19	85	45
De 05 a 09 years	9	10	12	12	98	24
De 10 a 14 years	14	21	8	17	73	35
De 15 a 19 years	55	30	48	52	151	68
De 20 a 24 years	61	71	79	73	199	148
De 25 a 29 years	91	108	132	123	219	128
De 30 a 34 years	117	148	163	187	333	232
De 35 a 39 years	146	170	202	189	371	285
De 40 a 44 years	230	280	332	340	481	376
De 45 a 49 years	384	453	568	570	778	685
De 50 a 54 years	583	735	819	893	1,142	1,036
De 55 a 59 years	733	1,026	1,161	1,335	1,808	1,645
De 60 a 64 years	1,022	1,363	1,604	1,823	2,392	2,285
De 65 a 69 years	1,269	1,716	1,996	2,293	3,234	3,143
De 70 a 74 years	1,549	2,175	2,596	2,819	3,983	3,671
De 75 a 79 years	1,736	2,298	2,880	3,282	4,562	4,172
De 80 years or older	2,551	3,702	4,726	5,438	8,023	7,489
Total	10,303	14,038	16,902	19,073	27,231	24,826

Table 4. Prevalent cases of AF in Colombia (Female) 2010-2015 for ages. Source: SISPRO.

Ages	2010	2011	2012	2013	2014	2015
De 0 a 4 years	8	9	16	7	44	16
De 05 a 09 years	3	6	7	7	50	11
De 10 a 14 years	8	10	3	8	34	15
De 15 a 19 years	25	18	29	29	81	35
De 20 a 24 years	25	26	40	39	113	77
De 25 a 29 years	21	34	44	36	108	52
De 30 a 34 years	37	35	69	64	147	82
De 35 a 39 years	45	68	80	72	172	119
De 40 a 44 years	88	103	132	128	211	150
De 45 a 49 years	166	193	237	233	345	290
De 50 a 54 years	254	300	391	399	514	445
De 55 a 59 years	350	476	528	624	854	750
De 60 a 64 years	442	598	708	808	1,101	1,014
De 65 a 69 years	546	772	917	1,037	1,479	1,385
De 70 a 74 years	775	1,063	1,231	1,392	1,941	1,731
De 75 a 79 years	989	1,254	1,614	1,796	2,453	2,249
De 80 years or older	1,570	2,221	2,768	3,243	4,705	4,389
Total	5,223	7,035	8,585	9,725	14,003	12,514

Table 5. Prevalent cases of AF (Male) in Colombia 2010-2015 for ages. Source: SISPRO.

Ages	2010	2011	2012	2013	2014	2015
De 0 a 4 years	6	11	14	12	41	29
De 05 a 09 years	4	4	3	5	46	11
De 10 a 14 years	6	11	5	7	34	13
De 15 a 19 years	29	11	18	22	70	33
De 20 a 24 years	36	45	39	34	86	71
De 25 a 29 years	70	74	88	87	111	76
De 30 a 34 years	80	113	94	123	186	150
De 35 a 39 years	101	102	122	117	199	166
De 40 a 44 years	142	177	200	212	270	226
De 45 a 49 years	217	258	331	337	433	395
De 50 a 54 years	329	434	427	493	627	591
De 55 a 59 years	383	550	633	711	954	895
De 60 a 64 years	579	764	896	1,014	1,290	1,270
De 65 a 69 years	722	941	1,077	1,255	1,753	1,757
De 70 a 74 years	769	1,110	1,362	1,425	2,039	1,935
De 75 a 79 years	745	1,040	1,263	1,482	2,105	1,921
De 80 years or older	979	1,478	1,952	2,189	3,311	3,095
Total	5,065	6,986	8,298	9,333	13,204	12,289

Table 6. Incident cases of AF in Colombia 2010-2015 for ages. Source: SISPRO.

Ages	2010	2011	2012	2013	2014	2015
De 0 a 4 years	4	3	4	1	1	1
De 05 a 09 years	1		1		2	5
De 10 a 14 years	3	3		3		5
De 15 a 19 years	13	4	10	9	15	9
De 20 a 24 years	6	5	9	11	19	13
De 25 a 29 years	15	12	24	11	15	18
De 30 a 34 years	18	27	25	19	30	36
De 35 a 39 years	32	22	34	27	55	41
De 40 a 44 years	38	57	50	52	57	42
De 45 a 49 years	77	88	95	90	105	101
De 50 a 54 years	104	105	117	147	166	159
De 55 a 59 years	136	176	178	194	255	231
De 60 a 64 years	172	220	246	284	354	329
De 65 a 69 years	241	256	276	382	497	505
De 70 a 74 years	276	352	351	439	639	582
De 75 a 79 years	318	398	415	531	636	648
De 80 years or older	448	550	614	797	1,199	1,228
Total	1,870	2,254	2,423	2,973	3,989	3,876

Table 7. Incident cases of AF (Female) in Colombia 2010-2015 for ages. Source: SISPRO.

Ages	2010	2011	2012	2013	2014	2015
De 0 a 4 years	2	1			1	1
De 05 a 09 years			1		2	2
De 10 a 14 years	1	2		1		1
De 15 a 19 years	4	1	8	5	9	5
De 20 a 24 years	4	3	6	5	10	6
De 25 a 29 years	5	3	11	3	5	6
De 30 a 34 years	9	6	14	5	7	6
De 35 a 39 years	10	7	15	8	18	19
De 40 a 44 years	20	25	27	19	20	15
De 45 a 49 years	38	42	46	35	52	36
De 50 a 54 years	47	44	61	58	79	63
De 55 a 59 years	58	80	78	96	121	97
De 60 a 64 years	86	85	116	112	161	162
De 65 a 69 years	114	114	130	180	224	231
De 70 a 74 years	144	169	166	214	314	279
De 75 a 79 years	176	211	224	295	341	365
De 80 years or more	284	333	361	485	713	743
Total	988	1,110	1,248	1,510	2,052	1,993

Table 8. Incident cases of AF (Male) in Colombia 2010-2015 for ages. Source: SISPRO.

Ages	2010	2011	2012	2013	2014	2015
De 0 a 4 years	1	2	3	1		
De 05 a 09 years						2
De 10 a 14 years	2	1		1		3
De 15 a 19 years	9	3	2	4	6	4
De 20 a 24 years	2	2	3	6	9	7
De 25 a 29 years	10	9	13	8	10	12
De 30 a 34 years	9	21	11	14	23	30
De 35 a 39 years	22	15	19	19	37	22
De 40 a 44 years	18	32	23	33	37	27
De 45 a 49 years	39	45	49	55	53	65
De 50 a 54 years	57	61	55	89	87	96
De 55 a 59 years	78	96	100	98	134	134
De 60 a 64 years	86	135	130	172	192	167
De 65 a 69 years	127	142	146	202	273	274
De 70 a 74 years	131	183	184	225	323	302
De 75 a 79 years	142	187	191	235	295	283
De 80 years or older	163	217	252	309	485	484
Total	879	1,143	1,171	1,458	1,933	1,879